National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 18652-18653 [2024-05435]
Download as PDF
<![CDATA[
18652
Federal Register / Vol. 89, No. 51 / Thursday, March 14, 2024 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Annual burden hours estimate
Number of
respondents
Form name
Average
burden per
response
(in hours)
Total annual
burden hour
User Registration ..............................................................................................................................
Data and Biospecimen Catalog Submission ....................................................................................
Institutional Certification Template ....................................................................................................
Data Request ....................................................................................................................................
Biospecimen Request .......................................................................................................................
Data Request Annual Progress Report ............................................................................................
Study Catalog Submission ................................................................................................................
External Resource Catalog Submission ...........................................................................................
Data Request Renewal .....................................................................................................................
900
36
36
150
4
240
2
4
42
1
1
1
1
1
1
1
1
1
5/60
2
5/60
1
1
30/60
30/60
15/60
10/60
75
72
3
150
4
120
1
1
7
Total ...........................................................................................................................................
1,414
1,414
........................
433
Dated: March 6, 2024.
Jennifer M. Guimond,
Project Clearance Liaison, Eunice Kennedy
Shriver National Institute of Child Health and
Human Development, National Institutes of
Health.
[FR Doc. 2024–05404 Filed 3–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Meeting
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
responses per
respondent
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
General Medical Sciences Council.
The meeting will be open to the
public as indicated below, with a short
public comment period at the end.
Attendance is limited by the space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
submit a request using the NIGMS
contact us form https://www.nigms.nih.
gov/Pages/ContactUs.aspx at least 5
days prior to the event. The open
session will also be videocast, closed
captioned, and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
VerDate Sep<11>2014
16:47 Mar 13, 2024
Jkt 262001
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
General Medical Sciences Council.
Date: May 16, 2024.
Open: 9:30 a.m. to 12:10 p.m.
Agenda: For the discussion of program
policies and issues; opening remarks; report
of the Director, NIGMS; and other business
of the Council.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1 &
E2, 45 Center Drive, Bethesda, MD 20892.
Closed: 1:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1 &
E2, 45 Center Drive, Bethesda, MD 20892.
Contact Person: Erica L. Brown, Ph.D.,
Director, Division of Extramural Activities,
National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 2AN24C, Bethesda,
MD 20892, 301–594–4499, erica.brown@
nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Electronic
copies are requested for the record.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://www.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
nigms.nih.gov/About/Council, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: March 11, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–05439 Filed 3–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RC2—NIDDK High
Impact, Interdisciplinary Science Review.
Date: March 27, 2024.
Time: 10:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892.
E:\FR\FM\14MRN1.SGM
14MRN1
Federal Register / Vol. 89, No. 51 / Thursday, March 14, 2024 / Notices
Contact Person: Charlene J. Repique, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes Of Health, Room 7347,
6707 Democracy Boulevard, Bethesda, MD
20892–5452, (301) 451–3638,
charlene.repique@nih.gov.
This notice is being published less than 15
days prior to the meeting due to scheduling
difficulties.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 11, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–05435 Filed 3–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
ddrumheller on DSK120RN23PROD with NOTICES1
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: New: The Center for
Substance Abuse Prevention Online
Reporting Tool and Grant
Programmatic Progress Report To
Replace Division of State Programs—
Management Reporting Tool (DSP–
MRT) (OMB No. 0930–0354)
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA), Center for Substance Abuse
Prevention (CSAP) is requesting
approval from the Office of Management
and Budget (OMB) to monitor CSAP
discretionary grant programs through
administration of a suite of data
collection instruments for grant
compliance and programmatic
performance monitoring. This package
describes the data collection activities
and proposed instruments. Grant
compliance monitoring will be
conducted via a single data collection
instrument to be completed by all CSAP
discretionary grant recipients.
Programmatic performance monitoring
VerDate Sep<11>2014
16:47 Mar 13, 2024
Jkt 262001
will be conducted via a suite of data
collection instruments with each
instrument tailored to a specific CSAP
discretionary program. This request for
data collection will replace OMB No.
0930–0354: Division of State
Programs—Management Reporting Tool.
CSAP intends to monitor six grant
programs through this data collection
effort:
• Strategic Prevention Framework—
Partnerships for Success (SPF–PFS): The
purpose of the SPF–PFS program is to
help reduce the onset and progression of
substance misuse and its related
problems by supporting the
development and delivery of state and
community substance misuse
prevention and mental health
promotion services. This program is
intended to promote substance use
prevention throughout a state
jurisdiction for individuals and families
by building and expanding the capacity
of local community prevention
providers to implement evidence-based
programs. In addition, the program is
intended to expand and strengthen the
capacity of local community prevention
providers to implement evidence-based
prevention programs. With this
program, SAMHSA aims to strengthen
state and community level prevention
capacity to identify and address local
substance use prevention concerns,
such as underage drinking, marijuana,
tobacco, electronic cigarettes, opioids,
methamphetamine, and heroin.
• Sober Truth on Preventing
Underage Drinking (STOP Act): The
purpose of this program is to prevent
and reduce alcohol use among youth
and young adults ages 12–20 in
communities throughout the United
States through evidence-based
screening, programs and curricula, brief
intervention strategies, consistent policy
enforcement, and environmental
changes that limit underage access to
alcohol as authorized by 942 U.S.C.
290bb–25b. The program aims to: (1)
address norms regarding alcohol use by
youth, (2) reduce opportunities for
underage drinking, (3) create changes in
underage drinking enforcement efforts,
(4) address penalties for underage use,
and/or (5) reduce negative consequences
associated with underage drinking.
• Strategic Prevention Framework for
Prescription Drugs (SPF Rx): The
purpose of the SPF Rx grant program is
to provide resources to help prevent and
address prescription drug misuse within
a State or locality. The program is
designed to raise awareness about the
dangers of sharing medications as well
as the risks of fake or counterfeit pills
purchased over social media or other
unknown sources, and work with
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
18653
pharmaceutical and medical
communities on the risks of
overprescribing. Whether addressed at
the state level or by an informed
community-based organization, the SPF
Rx program will raise community
awareness and bring prescription
substance misuse prevention activities
and education to schools, communities,
parents, prescribers, and their patients.
In addition, grant recipients will be
required to track reductions in opioid
related overdoses and incorporate
relevant prescription and overdose data
into strategic planning and future
programming.
• First Responders—Comprehensive
Addiction and Recovery Act (FR CARA):
The purpose of this program is to allow
first responders and members of other
key community sectors to administer a
drug or device approved or cleared
under the Federal Food, Drug, and
Cosmetic Act for emergency treatment
of known or suspected opioid overdose.
• Grants to Prevent Prescription
Drug/Opioid Overdose-Related Deaths
(PDO): The purpose of this program is
to support first responders and members
of other key community sectors to
administer a drug or device approved or
cleared under the Federal Food, Drug,
and Cosmetic Act (FD&C Act) for
emergency reversal of known or
suspected opioid overdose. Recipients
will train and provide resources to first
responders and members of other key
community sectors at the state, tribal,
and local levels on carrying and
administering a drug or device approved
or cleared under the FD&C Act for
emergency treatment of known or
suspected opioid overdose.
• Improving Access to Overdose
Treatment (ODTA): The purpose of this
program is to expand access to naloxone
and other Food and Drug
Administration (FDA) approved
overdose reversal medications for
emergency treatment of known or
suspected opioid overdose. The
recipients will collaborate with other
prescribers at the community level to
implement trainings on policies,
procedures, and models of care for
prescribing, co-prescribing, and
expanding access to naloxone and other
FDA-approved overdose reversal
medications to the specified population
of focus (i.e., rural or urban). With this
program SAMHSA aims to expand
access to naloxone and other FDA
approved overdose reversal medications
for emergency treatment of known or
suspected opioid overdose.
Grant compliance monitoring: All
SAMHSA awards require grantees to
submit performance and progress
reports through the electronic Research
E:\FR\FM\14MRN1.SGM
14MRN1
]]>Agencies
[Federal Register Volume 89, Number 51 (Thursday, March 14, 2024)]
[Notices]
[Pages 18652-18653]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-05435]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; RC2--NIDDK High Impact,
Interdisciplinary Science Review.
Date: March 27, 2024.
Time: 10:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NIDDK, Democracy II, Suite
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892.
[[Page 18653]]
Contact Person: Charlene J. Repique, Ph.D., Scientific Review
Officer, Review Branch, Division of Extramural Activities, NIDDK,
National Institutes Of Health, Room 7347, 6707 Democracy Boulevard,
Bethesda, MD 20892-5452, (301) 451-3638, [email protected].
This notice is being published less than 15 days prior to the
meeting due to scheduling difficulties.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: March 11, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-05435 Filed 3-13-24; 8:45 am]
BILLING CODE 4140-01-P
